Health Care

Regeneron’s latest J.P. Morgan Healthcare Conference updates reveal gene‑editing therapy for hearing loss, a promising weight‑loss dual agonist, and expanded Eylea indications, boosting investor confidence and market prospects.

Elevance Health Inc. will release Q1 2026 earnings at its January conference, with modest EPS growth expected and a $12.8 million settlement resolving residential‑treatment coverage denials—key insights for insurers, patients, and providers.

Eurofins Scientific’s recent EMAR insider filings show strong regulatory compliance, resilient shares, and a growing digital‑testing strategy amid European market volatility.

Discover how Cigna’s 2026 plan growth, Q4 2025 earnings, and partnership with Birches Health are boosting value‑based care, medication access, and regulatory compliance in U.S. health insurance.

Argenx shares swing after FDA grants priority review for Vyvgart’s new myasthenia gravis indication, boosting outlook and revealing the company’s strategy to diversify beyond oncology.

Roche Holding AG’s bold obesity and YL201 moves spotlight a rare diagnostics‑therapeutics synergy—explore how this could reshape its revenue and risk profile.

Deutsche Bank downgrades Haleon PLC to sell, citing slower earnings and rising costs; other analysts stay neutral, highlighting resilience and potential for strategic moves.

IPSEN’s IPN60340 earns FDA Breakthrough Therapy status for AML, delivering 58 % response in patients unsuitable for intensive chemo—plus promising Parkinson’s data from EPITOME.

Takeda’s strong oncology pipeline and AI‑powered drug‑development tools are boosting analyst confidence and positioning the company for growth in Japan and global markets.

Gilead Sciences’ future hinges on its HIV prevention shot, new Walgreens partnership, and oncology pipeline, amid divergent analyst outlooks and rising valuation concerns.